| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 66.7 | ¤775,527 | US |
| JNJ | Johnson & Johnson | 61.8 | ¤459,752 | US |
| ABT | Abbott Laboratories | 61.7 | ¤228,662 | US |
| MRK | Merck & Co., Inc. | 62.3 | ¤214,060 | US |
| TMO | Thermo Fisher Scientific Inc. | 52.2 | ¤198,088 | US |
| Symbol | Name | Grade | Market Cap | Country |
|---|---|---|---|---|
| ZBH | Zimmer Biomet Holdings, Inc. | 53.4 | ¤18,837 | US |
| DGX | Quest Diagnostics Incorporated | 57.8 | ¤20,439 | US |
| PODD | Insulet Corporation | 61.9 | ¤22,143 | US |
| LH | Labcorp Holdings Inc. | 50.5 | ¤22,989 | US |
| STE | STERIS plc | 62.9 | ¤23,193 | IE |
| Symbol | Name | Grade | Times* | Country |
|---|---|---|---|---|
| AMGN | Amgen Inc. | 61.9 | 31 | US |
| LLY | Eli Lilly and Company | 66.7 | 26 | US |
| PFE | Pfizer Inc. | 62.9 | 24 | US |
| DGX | Quest Diagnostics Incorporated | 57.8 | 22 | US |
| ZTS | Zoetis, Inc. Class A | 59.7 | 22 | US |
| BMY | Bristol-Myers Squibb Company | 57.1 | 21 | US |
| JNJ | Johnson & Johnson | 61.8 | 21 | US |
| TMO | Thermo Fisher Scientific Inc. | 52.2 | 21 | US |
| RMD | ResMed Inc. | 73.3 | 19 | US |
| GILD | Gilead Sciences, Inc. | 66.2 | 18 | US |
| Average Market Cap | ¤123,694 |
| Median Market Cap | ¤63,047 |
| Avg. 3 Mo. Dollar Vol. | ¤652,893,559 |
| Avg. 3 Mo. Trading Vol. | 5,075,061 |
| Last Rebalance Date | 09/22/2025 |
| Companies Replaced | 10 |
| Biggest Sector Increase | Health Care |
| Biggest Sector Decrease | Health Care |
| Trailing P/E Ratio (12 Mo.) | 28.7 |
| Forward P/E Ratio (12 Mo.) | 18.5 |
| Price/Book Ratio | 5.8 |
| Avg. Revenue Chg. - 3 Yr | 10.1% |
| Avg. Op. Income Chg. - 3 Yr. | 22.4% |
| Avg. EPS Growth - 3 Yr. | 4.8% |
| Avg. EPS Growth - 1 Yr. | 13.3% |
| Avg. Operating Margin | 18.5% |
| Avg. LT Debt to Total Capital | 42.0% |
| Avg. Return on Equity | 19.8% |
| Dividend Yield | 0.8% |
| US Health Care Index | 59.67 |
| United States Of America | 90.0% |
| Ireland | 6.67% |
| Switzerland | 3.33% |
